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a  b  s  t  r  a  c  t
Porcine  epidemic  diarrhea  virus  (PEDV)  is  the  causative  agent  of  porcine  epidemic  diarrhea,  a  highly
contagious  enteric  disease  of  swine.  The  Spike  (S) protein  is  one  of  the  main  structural  proteins  of PEDV
capable  of  inducing  neutralizing  antibodies  in vivo.  Herein,  we  generated  three  distinct  DNA  constructs
in  the eukaryotic  expression  plasmid  pVAX1;  one  encoding  the  S protein  [pVAX1-(PEDV-S)],  the sec-
ond  encoding  the  N-terminal  fragment  (S1)  [pVAX1-(PEDV-S1)]  containing  potent  antigenic  sites,  and
the third  expressing  the  porcine  interleukin-18  (pIL-18)  [pVAX1-(IL-18)].  Immunofluorescence  assays
in BHK-21  cells  demonstrated  successful  protein  expression  from  all  3 constructs.  Kunming  mice  were
injected  separately  with  each  of  these  constructs  or with  a pVAX1-(PEDV-S1)/pVAX1-(IL-18)  combi-
nation,  an  attenuated  PEDV  vaccine,  or vector  only  control.  Animals  were  examined  for  T lymphocyte
proliferation,  anti-PEDV  antibodies,  IFN-  and  IL-4  protein  levels,  and  cytotoxic  T  cell function  in  mouse
peripheral  blood  and spleen.  In all  cases,  results  showed  that  pVAX1-(PEDV-S)  and  the  combination  of
pVAX1-(PEDV-S1)  with  pVAX1-(IL-18)  induced  the  strongest  responses;  however,  pIL-18  had  no adjuvant
effects when given  in combination  with  pVAX1-(PEDV-S1).
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Porcine epidemic diarrhea virus (PEDV) causes porcine epi-
demic diarrhea (PED) which causes very high mortality in newborn
piglets. The disease was first reported in England in 1971 (Oldham,
1972). It has since been reported in many areas worldwide. The
first link between the disease and the PEDV was identified in
1977 (Pensaert and Bouck, 1978). The virus is an enveloped coro-
navirus with a positive-stranded RNA genome that encodes four
major structural proteins; spike (S), nucleocapsid (N), membrane
(M)  and envelope (E) proteins. Although conventional inactivated
and attenuated vaccines are widely used in some areas in China,
such vaccines have some drawbacks such as recovery of virulence,
spread of viruses, high cost and poor protection efficacy. Therefore,
development of novel and effective vaccines is necessary for control
of PED.
∗ Corresponding author at: College of Veterinary Medicine, Northeast Agricultural
University, 59 Mucai Street, Xiangfang District, Harbin 150030, China.
Tel.: +86 451 55190385; fax: +86 451 55103336.
E-mail addresses: renxf@neau.edu.cn, rxfemail@yahoo.com.cn (X. Ren).
Direct injection of plasmid DNA has been considered and eval-
uated as a candidate strategy for vaccination. A great number of
studies have shown that eukaryotic expression plasmids can induce
protective immune responses (Ding et al., 2005; Lillehoj et al., 2005;
Li et al., 2011). It is well known that the S protein of coronavi-
rus plays a crucial role in the induction of neutralizing antibodies
and has been used in the preparation of effective vaccines (Gomez
et al., 2000; Tuboly and Nagy, 2001). The N-terminal portion of
the S protein of several coronaviruses has been shown to contain
key antigenic sites responsible for eliciting humoral and cellular
immune responses (Delmas et al., 1986; Gebauer et al., 1991).
Interleukin-18 (IL-18) is a cytokine that was first cloned in 1995
from livers of propionibacterium acnes-treated mice (Okamura
et al., 1995). Functionally, IL-18 induces IFN- production, stim-
ulates proliferation of activated T cells, and enhances activities of
NK cells among other things (Muneta et al., 2000).
In this study, eukaryotic expression plasmids encoding the full-
length S protein, the N-terminal fragment of PEDV, or recombinant
porcine IL-18 (pIL-18) were constructed. Using a mouse model, we
compared host immune responses triggered by the full-length S
protein and its N-terminal fragment (S1) in the presence or the
absence of pIL-18 to determine if IL-18 offered any adjuvant effects
to the stimulation provided by the full-length or truncated forms
0168-1702/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
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Table 1
Experimental parameters and cytokine levels in the blood of immunized mice (¯XA − ¯XB ± s). Mice were immunized with pVAX-(IL-18) (A), pVAX1-(PEDV-S) (B), pVAX1-
(PEDV-S1) (C), pVAX1-(PEDV-S1) plus pVAX1-(IL-18) (D), attenuated PEDV vaccine (E), PBS (F) or pVAX1 (G). The number of mice, DNA dosage, and number of immunizations
are  indicated. The levels of IFN- in the serum of immunized mice were analyzed at 42 dpi using commercially available ELISA kits.
Group Number of mice Vaccine category Immunizing dose Number of
treatments
IFN- (pg/ml) IL-4 (pg/ml)
A 28 pVAX1-(IL-18) 100 g 3 1257.52 ± 49.49 116.04 ± 5.656
B  28 pVAX1-(PEDV-S) 100 g 3 1126.86 ± 64.34 202.17 ± 12.02
C  28 pVAX1-(PEDV-S1) 100 g 3 1079.63 ± 38.89 54.45 ± 1.414
D 28 pVAX1-(PEDV-
S1)  + pVAX1-(IL-18)
100 g 3 1678.24 ± 142.1 105.99 ± 4.949
100  g
E 28 Attenuated PEDV vaccine 100 g 3 215.07 ± 13.43 106.39 ± 4.242
F  28 PBS 100 g 3 133.34 ± 8.485 58.54 ± 6.363
G  28 pVAX1 100 g 3 167.64 ± 38.89 62.64 ± 3.535
 p < 0.01 (highly significant), compared with PBS, pVAX1, pVAX1-(IL-18), pVAX-(PEDV-S1) or attenuated PEDV vaccine.
of the S protein. These data may  facilitate the development of effi-
cacious viral gene vaccines.
2. Materials and methods
2.1. Construction of plasmids containing genes encoding PEDV-S,
PEDV-S1 or SwIL-18
The plasmid EasyT-S containing the full-length S gene of PEDV
strain CV777 was constructed in our laboratory by common
cloning techniques and used as a template for PCR amplification.
A sense primer P1 (5′-GGGGGGATCCATGAGGTCTTTAATTTAC), and
two antisense primers P2 (CCCCGAATTCTTAAATACTCATACTAAA)
and P3 (5′-CCCCGAATTCTCATCTCTGCACGTGGAC) which contain
BamHI (P1) and EcoRI (P2 and P3) restriction enzyme sites (under-
lined), were used for PCR. The amplification profile for the full
length S gene (primers P1/P2) was as follows: 95 ◦C for 5 min  fol-
lowed by 30 cycles of 94 ◦C for 2.5 min, 56.8 ◦C for 2.5 min, and
72 ◦C for 5 min. A final extension of 72 ◦C for 10 min  was per-
formed at the end of the cycling period. The amplification profile
for PEDV-S1 gene (primers P1/P3) was the same as for the PEDV-S
gene except that the annealing temperature was raised to 54.8 ◦C.
Plasmid pUC18-(IL-18) containing the full-length swine interleukin
18 gene was used as template for PCR. The sense and antisense
primers P4 (5′-GGGGGGATCCATGTACTTTGGCAAGCTT) and P5 (5′-
CCCCGAATTCCTAGTTCTTGTTTTGAACA) included BamHI and EcoRI
restriction enzyme sites (underlined), respectively. The PCR profiles
included 95 ◦C for 5 min  followed by 30 cycles of 94 ◦C for 0.5 min,
56.5 ◦C for 0.5 min, and 72 ◦C for 1 min  followed by a final exten-
sion of 72 ◦C for 10 min. All PCR products were purified, restriction
enzyme digested and ligated into the similarly digested eukaryotic
expression vector, pVAX1 (Invitrogen, USA). After transformation,
clones were picked and validated by DNA sequencing. The plasmids
were designated pVAX1-(PEDV-S), pVAX1-(PEDV-S1) and pVAX1-
(IL-18), respectively.
2.2. Preparation of plasmid DNA and immunofluorescence of
transformed BHK-21 cells
Plasmid DNAs were chromatographically purified from bac-
terial lysates (Qiagen, Germany), precipitated, and then washed
with ethanol. All plasmids were dissolved to 1 g/l in 0.1 M PBS.
BHK-21 cells from American Type Culture Collection (ATCC) were
cultured to 90% confluency in 6-well plates at 37 ◦C (approx. 24 h)
then transformed with 3 g of pVAX1-(PEDV-S), pVAX1-(PEDV-
S1), pVAX1-(IL-18), or pVAX1 using lipofectamine 2000. The next
day, indirect immunofluorescence assays were performed with
modifications as described (Liu et al., 2009; Sui et al., 2010; Li et al.,
2011). Formalin fixed cells were incubated for 1 h with polyclonal
antisera (1:200 dilution in 1% BSA) against PEDV (prepared in our
laboratory) or pIL-18 (prepared in our laboratory). After washing
with PBS, the cells were incubated in the dark with FITC-labeled
goat anti-rabbit IgG (1:1000) for 1 h. The green fluorescence signals
were analyzed by fluorescence microscopy (Leica, Germany).
2.3. Immunization of mice
All animal studies were pre-approved by the Animal Ethics
Committee of Northeast Agricultural University, China (approval
ID 1155-NCET-005). Prior to DNA vaccination, 6-week-old Kun-
ming mice (Harbin Veterinary Research Institute) were partitioned
into 7 groups (Table 1) and injected in the medial vastus mus-
cle with lidocaine hydrochloride (27 ga needle; 50 l of 0.8%
(v/v) in PBS). After 15 min, the mice received by similar injec-
tion, 100 g of pVAX1-(PEDV-S), pVAX1-(PEDV-S1), pVAX1-(IL18),
pVAX1-(PEDV-S1) + pVAX1-(IL18) (100 g each), attenuated vac-
cine PEDV, pVAX1, or PBS. The mice were boosted twice, each at
2-week intervals as shown in Table 1.
2.4. Antibody detection and T lymphocyte analysis
Peripheral blood was collected by orbital bleeds at 3 h and
then at 7, 14, 21, 28, 35 and 42 days post-immunization (dpi);
serum and T lymphocytes were subsequently prepared. For detect-
ing PEDV-specific antibody, recombinant PEDV-S1 protein purified
from pET-(PEDV-S1) transformed bacterial cells was diluted to
50 g/ml in 0.05 M NaHCO3. An ELISA was performed accord-
ing to Liu et al. (2009) with modification according to Li et al.
(2011). To assess antibody binding, ELISA wells were incubated
with o-phenylenediamine dihydrochloride substrate for 15 min.
The reactions were terminated with 50 l 2 M H2SO4 and the wells
read at 490 nm.
Peripheral blood lymphocytes were purified using lymphocyte
separation solution (Invitrogen, USA) according to the manufac-
turer’s instructions. Cells were suspended to 1 × 107 cells/ml in
RPMI 1640 medium containing 10% serum and further prepared as
described (Li et al., 2011). Prepared cells were then incubated at 4 ◦C
with FITC-conjugated anti-CD4+ T cell antibody or PE-conjugated
anti-CD8+ T cell antibody (1:1000 dilutions) (Zhongshan, China)
for 30 min. After incubation, the cells were washed with cold PBS
(3×),  suspended in PBS and subjected to flow cytometry. Splenic
lymphocytes were similarly prepared and analyzed.
2.5. Proliferation of T lymphocytes from immunized mice
Peripheral blood mononuclear cells and splenocytes from vacci-
nated and control mice were prepared for lymphocyte proliferation
assays as described (Li et al., 2011). Prepared cells (50 l of
2 × 106 cells/ml) were suspended in RPMI1640 containing 10%
serum then transferred to 96-well, flat-bottom plates. To each well,
50 l of medium containing either 20 g/ml purified recombinant
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PEDV-S1 protein or Concanavalin A (Con A; Sigma) was added; all
treatments were performed in triplicate. Plates were incubated for
72 h, supplemented with 10 l/well of 3-(4,5-dimethylthylthiazol-
2-yl)-2,5-diphenyltetrazoliumbromide (MTT), then incubated for
an additional 4 h. Reactions were terminated by adding an equal
volume of DMSO and incubating the plates at room temperature
for 10 min. Proliferation was determined from OD490 values.
2.6. Neutralization of PEDV with immune mouse sera
To determine if mice generated PEDV-neutralizing antibodies,
sera (1:100 dilution, 50 l) from DNA-vaccinated mice were mixed
with an equal volume of PEDV (105 pfu/ml) at 37 ◦C. After 1 h incu-
bation, the treated viruses were used to infect cultured African
green monkey kidney (Vero) cells in 96-well plates. The plates were
incubated at 37 ◦C in a 5% CO2 atmosphere and examined daily for
3 days for PEDV-specific cytopathic effects (CPE).
2.7. Indirect detection of IFN- and IL-4
Serum IFN- levels were analyzed with an IFN- detection kit
(Excell Bio, China) according to the manufacturer’s instructions. A
standard curve was generated using control IFN- diluted in PBS
at different concentrations beginning with 10,000 pg/ml, followed
by twofold serial dilutions between 2000 pg/ml and 61.25 pg/ml.
Dilutions were subsequently coated onto ELISA plates overnight at
37 ◦C. Sera (1:100) from 42 dpi mice were also coated onto ELISA
plates and used as primary antibodies in a parallel experiment to
evaluate the virus-derived IFN- response. HRP-conjugated goat-
anti mouse (1:2000) was used as secondary antibody in both the
control experiment and in the analysis of the mouse sera. The OD490
values and therefore pg/ml of IFN- in immunized mice were deter-
mined relative to the IFN- standard curve.
Serum IL-4 levels were similarly analyzed using an IL-4 detec-
tion kit (Excell Bio, China). Control IL-4 was serially diluted twofold
in PBS between 500 pg/ml and 7.8 pg/ml then coated onto ELISA
plates at 37 ◦C overnight. The ELISA was performed as above and
OD490 values (pg/ml) were determined relative to an IL-4 standard
curve.
2.8. Cytotoxicity (CTL) assay
Cytotoxicity was analyzed using a lactate dehydrogenase (LDH)
release assay kit according to the manufacturer’s instructions
(Jiancheng, Nanjing, China) using splenic lymphocytes and blood
from 42 dpi mice. Lymphocytes, suspended in complete RPMI 1640
medium were used as effector cells. Simultaneously, target Vero
cells were infected with PEDV at a titer of 100TCID50 for 36 h at
37 ◦C under 5% CO2. The effector cells were mixed the sensitized
target cells at 25:1, added to each well of a 96-well round-bottom
microplate, then incubated for 6 h at 37 ◦C. After centrifugation
at 1500 rpm for 10 min, 100 l of supernatant was collected and
transferred to a fresh 96-well flat-bottomed plate, followed by the
addition of 100 l/well of LDH assay reagent. The mixture was
allowed to incubate for 15 min  at 37 ◦C after which the OD490
was measured. Spontaneous release of LDH was determined using
samples prepared from target cells cultured in medium alone; max-
imum LDH release was measured using samples prepared by lysis
of target cells in medium containing 1% (v/v) Triton X-100. The
CTL was calculated using the following equation: [(experimental
release − spontaneous release)/(maximum release − spontaneous
release)] × 100. All experiments were performed in triplicate.
2.9. Statistical analysis
Statistical analysis of the data was  performed using SPSS 11.5
software; p < 0.05 and p < 0.01 were defined as statistically signifi-
cant and statistically very significant, respectively.
3. Results
3.1. In vitro expression of pVAX1-(PEDV-S), pVAX1-(PEDV-S1)
and pVAX1-(IL-18)
Sequence analysis of the subcloned pVAX1-(PEDV-S), pVAX1-
(PEDV-S1) and pVAX1-(IL-18) showed 100% identity with GenBank
accession numbers AF353511.1 (S and S1) and U58142 (IL-18),
respectively. We demonstrated by immunofluorescence assays that
the pVAX1-(PEDV-S), pVAX1-(PEDV-S1) and pVAX1-(IL-18) plas-
mids were successfully transformed into the BHK-21 cells and
expressed (Fig. 1).
3.2. T lymphocyte proliferation in blood and spleen
The specificities of blood and spleen T lymphocytes stimu-
lated with purified recombinant PEDV-S and -S1 were analyzed
with MTT  assays. Analyses using PBMC showed that at 14–42 dpi,
the proliferation in mice immunized with pVAX1-(PEDV-S1) and
pVAX1-(IL-18) was  highly significant (p < 0.01) relative to PBS and
pVAX1-(IL-18) controls (Fig. 2A). Between 28 and 42 dpi, prolifer-
ation of PBMC from mice immunized with pVAX1-(PEDV-S1) plus
pVAX1-(IL-18) was  significantly higher (p < 0.05) than proliferation
in mice immunized with pVAX1-(PEDV-S1) alone; no significant
differences (p > 0.05) were observed between the groups receiving
pVAX1-(PEDV-S) or pVAX1-(PEDV-S1).
As shown in Fig. 2B, by 14 dpi the proliferation levels of spleen
T lymphocytes treated with pVAX1-(PEDV-S) were highly sig-
nificant (p < 0.01) relative to PBS or pVAX1-(IL-18) controls. At
28 dpi, the proliferation levels using pVAX1-(PEDV-S1) in the
presence of pVAX1-(IL-18) were also highly significant (p < 0.01).
By 42 dpi, changes in proliferation levels relative to controls
remained highly significant (p < 0.01) using pVAX1-(PEDV-S1) with
pVAX1-(IL-18); however, no significant differences (p > 0.05) were
observed between control mice and those immunized with pVAX1-
(PEDV-S1) alone.
3.3. Changes in CD4+ and CD8+ T lymphocytes
Flow cytometry data showed that the levels of CD4+ and CD8+ T
lymphocytes in peripheral blood gradually increased beginning at
14 dpi and extended through 28 dpi. However, by 42 dpi, T lympho-
cyte populations in question decreased to control levels (Fig. 3A).
The levels of CD4+ cells in mice co-immunized with pVAX1-(IL-18)
were significantly higher (p < 0.01) than those in mice adminis-
tered pVAX1-(PEDV-S1) only at 28 dpi. Between 14 and 28 dpi, the
number of CD4+ T cells from mice immunized with pVAX1-(PEDV-
S1) and pVAX1-(IL-18) was  significantly higher (p < 0.05) than mice
immunized with vaccine only. In contrast, this difference was not
significant (p > 0.05) at 42 dpi. At 28 dpi, the levels of CD8+ cells
in mice co-immunized with pVAX1-(PEDV-S1) and pVAX1-(IL-18)
were significantly higher (p < 0.01) than those in mice administered
pVAX1-(PEDV-S1) only.
When spleen CD4+ lymphocyte numbers were examined by
flow cytometry (Fig. 3B) the results again showed that the group
receiving pVAX1-(PEDV-S1) and pVAX1-(IL-18) had a highly sig-
nificant impact (p < 0.01) on proliferation at 28–42 dpi where
proliferation peaked at 28 dpi and decreased thereafter. Anal-
yses of spleen-derived CD8+ T cells in animals treated with
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Fig. 1. Immunofluorescence analysis of cells transfected with recombinant plasmids. BHK-21 cells were transfected with pVAX, pVAX1-(IL-18), pVAX1-(PEDV-S) or pVAX1-
(PEDV-S1). Transient expression of proteins within the transfected cells was detected with anti-PEDV antibody [pVAX, pVAX1-(PEDV-S) and pVAX1-(PEDV-S1)] or with
anti-IL-18 antibody [pVAX1-(IL-18)]. The green signals reflect positive expression of proteins of interest. (For interpretation of the references to color in this figure legend,
the  reader is referred to the web  version of this article.)
pVAX1-(PEDV-S1) alone compared with those treated with pVAX1-
(PEDV-S1)/pVAX1-(IL-18) showed significant changes (p < 0.05) at
both 14 and 42 dpi.
3.4. Antibody detection in immunized mice
Serum antibody levels against PEDV were examined in mice
treated with plasmid DNA using an indirect ELISA (Fig. 4). In gen-
eral, between 7 and 42 dpi, the levels of PEDV antibodies in mice
immunized with pVAX1-(PEDV-S1) and pVAX1-(IL-18) were signif-
icantly higher (p < 0.01) than those receiving PBS or empty vector.
Also, at 21–42 dpi antibody levels induced by the combination
of pVAX1-(PEDV-S1) and pVAX1-(IL-18) were significantly higher
(p < 0.01) than those induced by pVAX1-(PEDV-S1) alone. Over the
same period, the level of PEDV antibody in mice immunized with
pVAX1-(PEDV-S) was highly significant (p < 0.01) relative to PBS
and empty vector. Also, antibody levels induced by pVAX1-(PEDV-
S) were highly significant (p < 0.01) relative to those induced by
pVAX1-(PEDV-S1) alone beginning at 21 dpi; by 28–42 dpi, this sig-
nificance decreased somewhat (p < 0.05).
3.5. Viral neutralization assay
Virus neutralizing assays showed that the serum from mice
treated with pVAX1-(PEDV-S1) plus pVAX1-(IL-18) developed 1:40
and 1:20 neutralizing antibodies that significantly (p < 0.01) neu-
tralized the virus relative to pVAX1-(PEDV-S1) only and control
immunized mice (Fig. 5). Significant neutralization was  observed
at serum dilutions of both 1:20 and 1:40.
3.6. Changes in the levels of serum IFN- and IL-4 in immunized
mice
Changes in serum IFN- and IL-4 levels in immunized mice
were analyzed using ELISA. The results showed that the levels of
IFN- in mice treated with pVAX1-(PEDV-S), pVAX1-(PEDV-S1),
pVAX1-(IL-18) or the pVAX1-(PEDV-S1)/pVAX1-(IL-18) combina-
tion were higher than in mice treated with PBS or pVAX1. The levels
of IFN- induced by pVAX1-(PEDV-S1) plus pVAX1-(IL-18) were
significantly higher than other groups (p < 0.01) (Table 1); how-
ever, they did not match the additive effects of pVAX1-(IL-18) and
pVAX1-(PEDV-S1) given separately. In like manner, approximately
2× increases were observed in the levels of IL-4 in all treatment
groups except for pVAX1-(PEDV-S) which exhibited 4× increases
over controls and pVAX1-(PEDV-S1) which did not induce any IL4
production.
3.7. Activity of CTL in blood and spleen
Cytotoxicity was  analyzed using the LDH release assay. The
results showed that CTL function in the peripheral blood of the mice
treated with pVAX1-(PEDV-S1) in combination with pVAX1-(IL-18)
was significantly higher than that observed with pVAX1-(PEDV-S1)
alone (p < 0.01). However, as with other studies, these values were
mirrored by the additive effects of pVAX1-(PEDV-S1) and pVAX1-
(IL-18) given separately. In like manner, CTL function in spleen
cells treated with pVAX1-(PEDV-S1) and pVAX1-(IL-18) was signif-
icantly greater (p < 0.01) than spleen cells from mice treated with
pVAX1-(PEDV-S1) alone (Fig. 6).
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Fig. 2. Changes in T lymphocyte numbers in the peripheral blood and spleens of immunized mice. Mice were immunized with pVAX1-(IL-18), pVAX1-(PEDV-S), pVAX1-
(PEDV-S1) and a combination of pVAX1-(PEDV-S1) and pVAX-(IL-18). In addition the attenuated PEDV vaccine, Con A, the empty vector pVAX1, and PBS were used as controls.
The  proliferation of T lymphocytes in mouse peripheral blood (A) and spleen (B) was  analyzed by conventional MTT  assays using recombinant PEDV-S1 protein and Con A
as  stimulating agents. The y-axis represents the lymphocyte proliferation index (OD490). p < 0.01 (highly significant), compared with PBS group and pVAX1 group; #p < 0.05
(significant), compared with pVAX1-(PEDV-S1) immunized group.
4. Discussion
Interleukin-18 is a cytokine known to improve the prolifera-
tion of T cells, and enhance activities of NK cells and CTL (Micallef
et al., 1996; Okamura et al., 1995; Tsutsui et al., 1997; Matsui et al.,
1997). Furthermore, in porcine mucosal tissues IL-18 may  advance
immune responses to invading pathogens (Foss et al., 2001). As
such, we hypothesized that IL-18 might act as a suitable adjuvant
to help protect against a Th1 inducing pathogen, i.e. PEDV. For
this reason, we evaluated synergistic effects between the PEDV-S1
and pIL-18 by means of DNA vaccination. Preliminary experiments
demonstrated via immunofluorescence assays that the cloned and
transiently transfected S and S1 genes along with the pIL-18 gene
were indeed capable of expressing the protein constructs in BHK-21
mouse cells.
Cytotoxic T-cell activities and IgG levels can provide readouts
for immune stimulation and protect hosts from virus infection
by neutralizing viral antigens, respectively. In this study, spleen
and blood-derived lymphocytes from immunized mice clearly
showed that co-immunization with pVAX1-(PEDV-S1) and pVAX1-
(IL-18) significantly induced T cell proliferation relative to controls
(<0.01). Cytotoxic T-cell activity was also validated indirectly by
monitoring cell lysis through increased LDH levels resulting from
damaged cells (Yokozawa et al., 2000). Elevated LDH levels were
observed in all but control treatments where the highest activi-
ties occurred in pVAX1-(PEDV-S1) and pVAX1-(IL-18) immunized
mice. Changes in the serum IgG levels in particular between 7 and
35 dpi clearly showed that the plasmid constructs induced effec-
tive humoral responses capable of neutralizing the virus and that
this neutralizing effect was strongest for the full-length S protein.
However, unexpectedly, pVAX1-(IL-18) functioned only in tandem
with pVAX1-(PEDV-S1) to affect both proliferative and virus neu-
tralizing responses but exerted no adjuvant effects. This is likely
the result of different and unrelated mechanisms that gave rise to
these changes.
It is well accepted that following polarization, Th1 cells secret
IFN- and IL-2 that mediate cellular immune responses, and Th2
cells secret IL-4 and IL-10 that help facilitate humoral immune
responses where IFN- and IL-4 levels are inversely regulated. In
the studies presented herein, the levels of IFN-were significantly
elevated in all non-control treatment groups. Unexpectedly, the
levels of IL-4 though low, were also elevated relative to controls
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Fig. 3. Changes in CD4+ and CD8+ T lymphocytes in the peripheral blood and spleens of immunized mice. Lymphocytes were collected from mice treated with, pVAX1-(IL-18),
pVAX1-(PEDV-S), pVAX1-(PEDV-S1) or a combination of pVAX1-(PEDV-S1) and pVAX-(IL-18). The attenuated PEDV vaccine, Con A, the empty vector pVAX1, and PBS were
used  as controls. Cells were subjected to flow cytometry to assess the numbers of CD4+ and CD8+ T lymphocytes in the blood (A) and spleens (B) of treated mice. In Fig
3A, p < 0.01 (highly significant) compared with pVAX1-(PEDV-S1) treated animals; #p <0.05 (significant), compared with attenuated PEDV vaccine. In (B), p < 0.01 (highly
significant) compared with the PBS and pVAX1 groups; #p <0.05 (significant), relative to pVAX1-(PEDV-S1) group and pVAX1-(IL-18) group.
Fig. 4. Anti-PEDV antibody levels in mice treated with pVAX1-(PEDV-S1) and pVAX1-(IL-18). Anti-PEDV serum antibodies in pVAX1-(PEDV-S), pVAX1-(PEDV-S1) and/or
pVAX1-(IL-18) immunized mice were detected by indirect ELISA at different time points following the injection of the plasmid DNAs. The OD490 was monitored as a function
of  time over a period of 42 days. p < 0.01 (highly significant), compared with PBS, pVAX1 and pVAX1-(PEDV-S1) treatment groups; #p <0.05 (significant), relative to PBS,
pVAX1  and pVAX1-(PEDV-S1) groups.
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Fig. 5. Levels of neutralizing antibodies in mice treated with pVAX1-(PEDV-S1) and pVAX1-(IL-18). Anti-PEDV antibodies in immunized mice were detected by indirect ELISA
at  different serum dilutions following the injection of pVAX1-(IL-18), pVAX1-(PEDV-S), pVAX1-(PEDV-S1) and a combination of pVAX1-(PEDV-S1) and pVAX-(IL-18). The
attenuated PEDV vaccine, Con A the empty vector pVAX1, and PBS were used as controls. The OD490 was monitored as a function of time over a period of 42 days. p < 0.01
(highly  significant) relative to the pVAX1-(PEDV-S1) only group.
Fig. 6. Activity of CTLs in the peripheral blood and spleen. Cytotoxicity was  analyzed using the LDH release assay. The release of LDH which is directly proportional to CTL
activity was  monitored as a function of time over period of 42 days. p < 0.01 (highly significant) relative to the pVAX1-(PEDV-S1) immunized group.
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in all treatment groups except animals given pVAX1-(PEDV-S1)
which generated no IL4 response. The dual elevation of IFN- and
IL-4 has been observed elsewhere in GI nematode-infected cattle
(Canals et al., 1997) and in cattle infected with the bovine viral
diarrhea virus (Waldvogel et al., 2000) or vaccinated against the
bovine respiratory syncytial virus (Miao et al., 2004). It is still
unclear as to why such a deviation from the norm occurred here;
however, some studies suggest that the level of infection and there-
fore the level of antigen presentation can affect Th1/Th2 profiles
(Claerebout et al., 2005). These data in conjunction with virus neu-
tralization studies suggest that IFN- does not play a major role in
protection.
To the best of our knowledge, this is the first time that the
immunological efficacies triggered by full-length S protein or the
S1 portion of PEDV were compared using a mouse model. In con-
trast to our work on TEGV (Ren et al., 2006), results presented here
showed that the full-length S gene unilaterally induced a better
immune response than the truncated form of the protein; how-
ever, this may  result from poor protein folding or less than optimal
presentation of the shortened form to the host immune system.
Future studies will examine this phenomenon more closely while
investigating additional cytokines that enhance antibody produc-
tion rather than Th1 type cytokines before attempting to transfer
this technology to studies in swine.
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